Lipidic cubic phases (LCPs) can reduce Pd 2+ salts to palladium nanoparticles (PdNPs) of ∼5 nm size in their confined water channels under mild conditions. The resulting PdNP-containing LCPs were used as nanoreactor scaffolds to catalyze Suzuki–Miyaura cross-coupling reactions in the aqueous channels of the mesophase. To turn on catalysis, PdNP-containing LCPs were activated by swelling the aqueous channels of the lipidic framework, thereby enabling diffusion of the water-soluble substrates to the catalysts. The mesophases play a threefold role: they act as reducing agents for Pd 2+, as limiting templates for their growth, and as support. The system was characterized and investigated by small-angle X-ray scattering (SAXS), cryo-transmission electron microscopy, dynamic light scattering, and nuclear magnetic resonance. Bulk LCPs and three dispersed palladium/lipid hybrid nanoparticle types were applied in the catalysis. The latter—liposomes, hexosomes, and cubosomes—can be obtained by design through combination of lipids and additives. The Suzuki–Miyaura cross-coupling of 5-iodo-2′-deoxyuridine and phenylboronic acid was used as a model reaction to study these systems. Bulk Pd-LCPs deliver the Suzuki–Miyaura product in 24 h in conversions up to 98% at room temperature, whereas with palladium/lipid dispersions at 40 °C, 68% of the starting material was transformed to the product after 72 h.
No takes yet. Share an insight, caveat, or question.
Duss et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: